An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib
- Registry ID
- EUCTR2008-000357-35
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Novartis Pharma GmbH
- Start date
- 2008-09-24
- Completion date
- 2014-08-13
- Last update
- 2026-08-16
Conditions
- gastrointestinal stromal tumors
- metastatic or unresectable gastrointestinal stromal tumor in patients resistant to imatinib or sunitinib
- adult patients with unresectable or metastatic gastrointestinal stromal tumors showing progression of disease or intolerance to imatinib and/or sunitinib
Summary
To evaluate the preliminary efficacy of nilotinib in pretreated patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as stable disease (SD), partial response (PR) or complete response (CR) during the first 4 months according to RECIST criteria.
Locations
- , , Italy
- , , UK
- , , Germany
View on source registry